NVIDIA Announces Upcoming Events for Financial Community

SANTA CLARA, CA -- (Marketwired) -- 02/10/17 -- NVIDIA will present at the following events for the financial community:

Morgan Stanley Technology, Media & Telecom Conference Wednesday, March 1, 10:25 a.m. Pacific time Palace Hotel, 2 New Montgomery Street, San Francisco, Calif.

Raymond James 38th Annual Institutional Investors Conference Monday, March 6, 6:50 a.m. Pacific time JW Marriott Grande Lakes, 4040 Central Florida Pkwy, Orlando, Fla.

Interested parties can listen to a live audio webcast of NVIDIA's presentations at this event, available on the NVIDIA website at www.nvidia.com/investor. A replay of the webcast will be available for 90 days afterward.

Keep Current on NVIDIA Subscribe to the NVIDIA blog, follow us on Facebook, Google+, Twitter, LinkedIn and Instagram, and view NVIDIA videos on YouTube and images on Flickr.

About NVIDIA NVIDIA (NASDAQ: NVDA) is the AI computing company. Its invention of the GPU in 1999 sparked the growth of the PC gaming market, redefined modern computer graphics and revolutionized parallel computing. More recently, GPU deep learning ignited modern AI -- the next era of computing -- with the GPU acting as the brain of computers, robots and self-driving cars that can perceive and understand the world. More information at http://nvidianews.nvidia.com/.

© 2017 NVIDIA Corporation. All rights reserved. NVIDIA and the NVIDIA logo are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries.

For further information, contact:
Arnab Chanda
Investor Relations
NVIDIA Corporation
(408) 566-6036
[email protected]

Robert Sherbin
Corporate Communications
NVIDIA Corporation
(408) 566-5150
[email protected]

Source: NVIDIA

You May Also Be Interested In

• Active options: NVDA TSLA AAPL INTC ORCL MSFT MU AMZN
• Active options: NVDA TSLA INTC ORCL AAPL MSFT GOOGL AMZN MU
• Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Ann